SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study

Last updated: May 18, 2020
Sponsor: Children's Hospital Medical Center, Cincinnati
Overall Status: Completed

Phase

2/3

Condition

Esophageal Disorders

Ulcers

Gastrointestinal Diseases And Disorders

Treatment

N/A

Clinical Study ID

NCT02778867
2015-1949
U54AI117804
  • Ages 18-60
  • All Genders

Study Summary

The purpose of this interventional study is to test and compare the effectiveness of two elimination diets—the 1-food elimination diet (1FED, milk only) and the 6-food elimination diet (6FED, milk, egg, wheat, soy, tree nut/peanuts, and fish/shellfish). The study will also test the effectiveness of swallowed glucocorticoid therapy in some of the study participants for whom diet therapy was not effective.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Have diagnosis of EoE (based on consensus criteria)

  • Have histologically confirmed active disease >15 eosinophils/hpf in either distal orproximal esophagus within 12 weeks of screening visit

  • Symptomatic (have experienced symptoms within the last month prior to enrollment)

  • Proton pump inhibitor (PPI) confirmation

  • Have a negative urine pregnancy test at screening if of childbearing potential

Exclusion

Exclusion Criteria:

  • Have been treated with topical swallowed steroids within the last 2 months or systemicsteroids within the last 3 months

  • Have pathological eosinophilia in segments of the GI tract other than the esophagusdetermined by local review

  • Have been diagnosed with a GI malabsorption disorder (i.e., Inflammatory boweldisease, Crohn's disease) or Celiac disease

  • Are currently on dietary therapy strictly avoiding milk or on a 6FED

  • Have concurrent H pylori gastritis or parasitic infection

  • Have history of anaphylaxis to milk (with current avoidance of milk)

  • Have previously failed strict dietary therapy clearly documented with one of theseregimens or topical steroid treatment (i.e. have achieved histological remission of <15 eos/hpf after having been on fluticasone or >1mg budesonide per day).

  • Use of investigational drugs within 4 weeks (one month) prior to enrollment

  • Are concurrently receiving any of the prohibited medications for the study

  • On immunotherapy for pollen (if not on maintenance therapy) or immunoglobulin-E (IgE) -mediated food allergy

  • Past or current medical problems or findings from physical examination or laboratorytesting that are not listed above, which, in the opinion of the investigator, may poseadditional risks from participation in the study, may interfere with the participant'sability to comply with study requirements or that may impact the quality orinterpretation of the data obtained from the study.

Study Design

Total Participants: 129
Study Start date:
May 20, 2016
Estimated Completion Date:
May 29, 2019

Study Description

This study will consist of two phases, plus a screening period. During the screening period, subject eligibility for the study will be determined. During Phase 1, qualified participants will be randomly assigned to one of two elimination diet therapies--the 1FED or the 6FED. Participants will remain on the assigned dietary therapy for 6 weeks. At the end of 6 weeks of therapy, esophageal biopsies from participant's standard of care (i.e. normal, routine care) endoscopy will be evaluated to determine disease status. Participants whose EoE is in remission (i.e. <15 eos/hpf) will be done with the study.

Participants whose EoE is still active (i.e. ≥15 eos/hpf) will have the option to continue into Phase 2 of the study. During Phase 2, participants who were on 1FED in Phase 1 will receive 6FED therapy for 6 weeks, and participants who were on 6FED during Phase 1 will receive swallowed glucocorticoid (SGC) therapy for 6 weeks. At the end of 6 weeks of therapy, esophageal biopsies from participant's standard of care (i.e. normal, routine care) endoscopy will be evaluated to determine disease status.

Connect with a study center

  • University of California, San Diego

    La Jolla, California 92093
    United States

    Site Not Available

  • Northwestern University

    Chicago, Illinois 60208
    United States

    Site Not Available

  • Tufts University

    Boston, Massachusetts 02111
    United States

    Site Not Available

  • Mayo Clinic

    Rochester, Minnesota 55905
    United States

    Site Not Available

  • Icahn School of Medicine at Mount Sinai

    New York, New York 10029
    United States

    Site Not Available

  • University of North Carolina, Chapel Hill

    Chapel Hill, North Carolina 27599
    United States

    Site Not Available

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio 45229
    United States

    Site Not Available

  • University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • University of Utah

    Salt Lake City, Utah 84132
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.